Analyzing the immune response in relapsed Acute Myeloid Leukemia after stem cell transplant

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to analyze the immunobiology of Acute Myeloid Leukemia (AML) relapses following allogeneic hematopoietic stem cell transplantation (HSCT). It involves both retrospective and prospective data collection from multiple centers, focusing on the identification of leukemic relapses characterized by Human Leukocyte Antigens loss and changes in gene expression. The goal is to develop personalized therapeutic pathways and guidelines to improve treatment strategies and patient outcomes. The study leverages collaboration among Italian transplant centers to standardize therapeutic management and promote innovative clinical studies.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Adult patients with Acute Myeloid Leukemia, who relapse after allogeneic transplantation from either family or unrelated donors, regardless of the cellular source of the transplant (bone marrow, mobilized peripheral stem cells or cord blood), who have signed the informed consent of the study;
* For the coordinating center, all patients who have previously signed informed consent to the "Hematological Neoplasms Biobank" and for which samples, stored in the Biobank are available.
* For the other centers, all patients who have previously signed an informed consent, aimed at the prior authorization for the storage of samples in the biobank of the aforementioned center, according to centers own practice, and for which samples, stored in a Biobank, are available.

Exclusion Criteria:

* Participation in clinical protocols that expressly exclude the possibility of participating in other studies.

Where it's running

• IRCCS Ospedale San Raffaele
  Milan, Milano, Italy Recruiting

Study contacts

• Principal investigator: Fabio Ciceri, MD — IRCCS Ospedale San Raffaele
• Study coordinator: Fabio Ciceri, MD
• Email: ciceri.clinicaltrials@hsr.it
• Phone: +39 02-2643-3093

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Personalized T-cell therapy with a DC/AML fusion vaccine plus decitabine and venetoclax for AML

  This will try combining a personalized T-cell therapy and a DC/AML fusion vaccine with decitabine and venetoclax for people with newly diagnosed or relapsed AML to see if it is safe and can boost anti-leukemia immunity.

  Recruiting Phase 1 Beth Israel Deaconess Medical Center · Boston, Massachusetts · NCT07374029

• Combining cytokine-induced memory-like natural killer cells with atezolizumab for relapsed or refractory AML

  This trial will test whether giving cytokine-induced memory-like natural killer cells together with atezolizumab is safe and might help adults with relapsed or refractory acute myeloid leukemia.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07011004

• Long-term safety follow-up of ARD103 CAR-T cells in relapsed/refractory AML and MDS

  This long-term follow-up study checks whether ARD103 CAR-T cell therapy remains safe for patients with relapsed or refractory AML or MDS after the initial treatment.

  Recruiting at 3 sites ARCE Therapeutics, Inc. · Charlotte, North Carolina and 2 other locations · NCT06906380

• Treatment with ARD103 CAR-T therapy for patients with relapsed or refractory AML or MDS

  This study is testing a new CAR-T therapy called ARD103 to see if it can help people with relapsed or hard-to-treat acute myeloid leukemia or myelodysplastic syndrome.

  Recruiting at 3 sites Phase 1/2 ARCE Therapeutics, Inc. · Charlotte, North Carolina and 2 other locations · NCT06680752

• MT-401-OTS treatment for relapsed AML or high‑risk MDS (safety focus)

  This trial will test whether escalating doses of an experimental off‑the‑shelf cell therapy called MT-401-OTS are safe and can reduce residual disease in adults aged 65 and older with relapsed or persistent AML or high‑risk MDS with low blast counts.

  Recruiting at 3 sites Phase 1 Marker Therapeutics, Inc. · Duarte, California and 2 other locations · NCT06552416

• Using Sorafenib to Prevent Relapse After Stem Cell Transplantation

  This study is testing if the drug sorafenib can help prevent relapse in patients with high-risk blood cancers after they receive a stem cell transplant.

  Recruiting Phase 2 St. Petersburg State Pavlov Medical University · Saint Petersburg · NCT06532084

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.